Background: Hypertension and obesity are major risk factors for health problems and cardiovascular diseases in developing and developed countries. There is limited evidence available on the correlation between high blood pressure and obesity despite their close association.
Methods: The current study aimed to find the correlation between anthropometric measurements, lipid profile, visfatin, apelin, and blood pressure parameters in 31 newly diagnosed hypertensive patients and 32 enalapril-treated hypertensive patients.
Results: In enalapril treated patients, a significant negative relationship between visfatin and triglyceride (TG). Conversely, there is a positive correlation between visfatin and HDL. Moreover, visfatin expressed a negative correlation with VLDL. Concerning the newly diagnosed hypertensive group, a non-significant correlation was found between serum visfatin and lipid profile parameters. Additionally, a significant negative correlation between apelin and DBP in enalapril treated patients. Moreover, significant negative correlation between apelin and SBP in enalapril treated patients. On the other hand, a non-significant correlation between apelin and blood pressure parameters in the newly diagnosed hypertensive group was found. Moreover, there was a significant positive relationship between BMI and visfatin by comparing these two variables in all studied group participants.
Conclusion: We concluded that anthropometric measurements, adipokines, and lipid profiles most closely relate to high blood pressure in hypertensive patients.
enalapril, adipokine, lipid, hypertension
Archer, S. L. (2005). Pre–B-cell Colony-Enhancing Factor Regulates Vascular Smooth Muscle Maturation Through a NAD+-Dependent Mechanism: Recognition of a New Mechanism for Cell Diversity and Redox Regulation of Vascular Tone and Remodeling. In (Vol. 97, pp. 4-7): Am Heart Assoc.
Chang, Y. H., Chang, D. M., Lin, K. C., Shin, S. J., & Lee, Y. J. (2011). Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review. Diabetes/metabolism research and reviews, 27(6), 515-527.
Chen, Y., Pitzer, A. L., Li, X., Li, P. L., Wang, L., & Zhang, Y. (2015). Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter‐endothelial junction disruption: role of HMGB 1. Journal of cellular and molecular medicine, 19(12), 2715-2727.
Engin, A. (2017). Endothelial dysfunction in obesity. Obesity and lipotoxicity, 345-379.
Garten, A., Schuster, S., Penke, M., Gorski, T., De Giorgis, T., & Kiess, W. (2015). Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nature Reviews Endocrinology, 11(9), 535-546.
Hung, W.-W., Hsieh, T.-J., Lin, T., Chou, P.-C., Hsiao, P.-J., Lin, K.-D., & Shin, S.-J. (2011). Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes. Cardiovascular drugs and therapy, 25, 3-12.
Jin, H., Jiang, B., Tang, J., Lu, W., Wang, W., Zhou, L., Shang, W., Li, F., Ma, Q., & Yang, Y. (2008). Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes research and clinical practice, 79(3), 412-418.
Katsimardou, A., Imprialos, K., Stavropoulos, K., Sachinidis, A., Doumas, M., & Athyros, V. (2020). Hypertension in metabolic syndrome: novel insights. Current hypertension reviews, 16(1), 12-18.
Koka, S., Xia, M., Zhang, C., Zhang, Y., Li, P.-L., & Boini, K. M. (2019). Podocyte NLRP3 inflammasome activation and formation by adipokine visfatin. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology, 53(2), 355.
Pagano, C., Pilon, C., Olivieri, M., Mason, P., Fabris, R., Serra, R., Milan, G., Rossato, M., Federspil, G., & Vettor, R. (2006). Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. The Journal of Clinical Endocrinology & Metabolism, 91(8), 3165-3170.
Papadopoulos, D. P., Mourouzis, I., Faselis, C., Perrea, D., Makris, T., Tsioufis, C., & Papademetriou, V. (2013). Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. The Journal of Clinical Hypertension, 15(5), 333-336.
Pham, D.-V., & Park, P.-H. (2020). Recent insights on modulation of inflammasomes by adipokines: a critical event for the pathogenesis of obesity and metabolism-associated diseases. Archives of pharmacal research, 43, 997-1016.
Romacho, T., Valencia, I., Ramos-González, M., Vallejo, S., López-Esteban, M., Lorenzo, O., Cannata, P., Romero, A., San Hipólito-Luengo, A., & Gómez-Cerezo, J. F. (2020). Visfatin/eNampt induces endothelial dysfunction in vivo: A role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific reports, 10(1), 5386.
Rotkegel, S., Chudek, J., Spiechowicz-Zaton, U., Ficek, R., Adamczak, M., & Wiecek, A. (2013). The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity. Kidney and Blood Pressure Research, 37(2-3), 124-131.
Sosnowska, B., Mazidi, M., Penson, P., Gluba-Brzózka, A., Rysz, J., & Banach, M. (2017). The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis, 265, 275-282.
Wang, B., & Tontonoz, P. (2018). Liver X receptors in lipid signalling and membrane homeostasis. Nature Reviews Endocrinology, 14(8), 452-463.
Wang, P., van Greevenbroek, M. M., Bouwman, F. G., Brouwers, M. C., van der Kallen, C. J., Smit, E., Keijer, J., & Mariman, E. C. (2007). The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflügers Archiv-European Journal of Physiology, 454, 971-976.
Wu, H., CHeng, X. W., Hao, C., ZHang, Z., Yao, H., MuroHara, T., & Dai, Q. (2014). Regulation of apelin and its receptor expression in adipose tissues of obesity rats with hypertension and cultured 3T3-L1 adipocytes. Experimental animals, 63(2), 257-267.
Xia, M., Boini, K. M., Abais, J. M., Xu, M., Zhang, Y., & Li, P.-L. (2014). Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. The American journal of pathology, 184(5), 1617-1628.
Yamaguchi, S., Franczyk, M. P., Chondronikola, M., Qi, N., Gunawardana, S. C., Stromsdorfer, K. L., Porter, L. C., Wozniak, D. F., Sasaki, Y., & Rensing, N. (2019). Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice. Proceedings of the National Academy of Sciences, 116(47), 23822-23828.
Yamaguchi, S., & Yoshino, J. (2017). Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy. Bioessays, 39(5), 1600227.
Zhong, O., Wang, J., Tan, Y., Lei, X., & Tang, Z. (2022). Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: A meta-analysis. Nutrition & Metabolism, 19(1), 20.
Zhou, Q., Cao, J., & Chen, L. (2016). Apelin/APJ system: a novel therapeutic target for oxidative stress-related inflammatory diseases. International journal of molecular medicine, 37(5), 1159-1169.
Zhu, P., Huang, F., Lin, F., Yuan, Y., Chen, F., & Li, Q. (2013). Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population. Annals of medicine, 45(7), 494-498.
